Taysha Gene Therapies
Stock Forecast, Prediction & Price Target
Taysha Gene Therapies Financial Estimates
Taysha Gene Therapies Revenue Estimates
Taysha Gene Therapies EBITDA Estimates
Taysha Gene Therapies Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $2.50M 0% | $15.45M 517.54% | Avg: $5.74M Low: $4.05M High: $7.09M avg. -62.80% | Avg: $37.51M Low: $25.41M High: $48.86M avg. 552.78% | Avg: $51.66M Low: $34.99M High: $67.29M avg. 37.70% | Avg: $125.91M Low: $85.28M High: $163.98M avg. 143.70% |
Net Income
% change YoY
| $-175.45M N/A | $-169.58M 3.35% | $-111.56M 34.21% | Avg: $-102.90M Low: $-75.47M High: $-39.48M avg. 7.75% | Avg: $-84.62M Low: $-78.96M High: $12.77M avg. 17.76% | Avg: $-45.31M Low: $-63.13M High: $-26.30M avg. 46.44% | Avg: $-13.06M Low: $-18.19M High: $-7.58M avg. 71.17% |
EBITDA
% change YoY
| $-173.09M N/A | $-125.79M 27.32% | $-105.19M 16.37% | Avg: $1.14M Low: $811.64K High: $1.41M avg. 101.09% | Avg: $7.50M Low: $5.08M High: $9.77M avg. 552.78% | Avg: $10.33M Low: $6.99M High: $13.45M avg. 37.70% | Avg: $25.18M Low: $17.05M High: $32.79M avg. 143.70% |
EPS
% change YoY
| -$4.66 N/A | -$3.86 17.16% | -$0.96 75.12% | Avg: -$0.47 Low: -$0.65 High: -$0.34 avg. 51.13% | Avg: -$0.41 Low: -$0.68 High: $0.11 avg. 13.66% | Avg: -$0.39 Low: -$0.54 High: -$0.23 avg. 3.63% | Avg: -$0.11 Low: -$0.16 High: -$0.07 avg. 71.17% |
Operating Expenses
% change YoY
| $173.26M N/A | $128.52M -25.82% | $87.89M -31.61% | Avg: $22.74M Low: $16.06M High: $28.08M avg. -74.11% | Avg: $148.48M Low: $100.56M High: $193.38M avg. 552.78% | Avg: $204.47M Low: $138.49M High: $266.30M avg. 37.70% | Avg: $498.30M Low: $337.50M High: $648.99M avg. 143.70% |
FAQ
What is Taysha Gene Therapies stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 35.78% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -75.47M, average is -102.90M and high is -39.48M.
What is Taysha Gene Therapies stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 167.84% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $4.05M, average is $5.74M and high is $7.09M.
What is Taysha Gene Therapies stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 34.90% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$0.65, average is -$0.47 and high is $-0.34.
What is the best performing analyst?
In the last twelve months analysts have been covering Taysha Gene Therapies stock. The most successful analyst is Christopher Raymond.